Yonghong Ran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yonghong Ran has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Yuhui Hao
State Key Laboratory of Trauma and Chemical Poisoning, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Army Medical University, Chongqing, China
5 shared publications Juan Li
State Key Laboratory of Trauma and Chemical Poisoning, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Army Medical University, Chongqing, China
4 shared publicationsYazhen Zhao
State Key Laboratory of Trauma and Chemical Poisoning, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Army Medical University, Chongqing, China
4 shared publicationsLi Shen
State Key Laboratory of Trauma and Chemical Poisoning, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Army Medical University, Chongqing, China
3 shared publicationsWenrun Li
State Key Laboratory of Trauma and Chemical Poisoning, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Army Medical University, Chongqing, China
3 shared publicationsYong Li
State Key Laboratory of Trauma and Chemical Poisoning, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Army Medical University, Chongqing, China
3 shared publications
Latest Publications
- 11 July 2026
- Published by Springer Nature in BioMetals
- Vol. 39 (5) , 1399-1420
Recent advances in therapeutic agents for uranium poisoning: a comprehensive review
Uranium—an emerging pollutant that exhibits both radioactivity and heavy metal toxicity—is extensively used in nuclear fuel and military applications. Occupational and environmental exposure during its extraction, production, and utilization poses significant health risks. Consequently, developing effective countermeasures against uranium poisoning remains a critical challenge in the field of medical research. This review systematically introduces the latest experimental progress in research on drugs for treating uranium toxicity. It specifically elucidates the mechanisms and efficacy evaluations of multiple detoxification strategies, including chelating agents, nanomedicines, biosynthetic compounds, small molecules, natural medicines, and plant extracts. By analyzing innovative drug design principles and evaluating their mechanistic effects on uranium toxicity, this work provides critical insights for the future development of highly effective and low-toxicity novel therapies for uranium poisoning. Graphical abstract
- 11 July 2026
- Published by Springer Nature in BioMetals
- Vol. 39 (5) , 1399-1420
Recent advances in therapeutic agents for uranium poisoning: a comprehensive review
Uranium—an emerging pollutant that exhibits both radioactivity and heavy metal toxicity—is extensively used in nuclear fuel and military applications. Occupational and environmental exposure during its extraction, production, and utilization poses significant health risks. Consequently, developing effective countermeasures against uranium poisoning remains a critical challenge in the field of medical research. This review systematically introduces the latest experimental progress in research on drugs for treating uranium toxicity. It specifically elucidates the mechanisms and efficacy evaluations of multiple detoxification strategies, including chelating agents, nanomedicines, biosynthetic compounds, small molecules, natural medicines, and plant extracts. By analyzing innovative drug design principles and evaluating their mechanistic effects on uranium toxicity, this work provides critical insights for the future development of highly effective and low-toxicity novel therapies for uranium poisoning. Graphical abstract
- 2 April 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1) , 86
Multifaceted regulation of immune cells in radiation-induced pulmonary fibrosis: from mechanistic insights to targeted therapies
Background Radiation induced pulmonary fibrosis (RIPF) is a life threatening and frequent complication that can occur after radiotherapy to thoracic cancers, and has a complicated pathogenesis and few treatment options. Recent data suggest that immune cells are the centerpiece of this mechanism, and constitute a complex system of regulation. Objective This review systematically summarizes the dynamic roles and molecular mechanisms of key immune cells in RIPF initiation and progression, and reviews current advances in targeted immunotherapies. Methods A comprehensive literature search was conducted in PubMed and Web of Science for studies on immune regulation and therapeutic strategies in RIPF. Results RIPF exhibits profound spatiotemporal heterogeneity, with immune cell subsets evolving dynamically from inflammation to fibrosis. Macrophages transcend the M1/M2 dichotomy, encompassing specialized subsets. Neutrophils promote fibrosis via NETosis and STAT3/NLRP3 pathways, while eosinophils switch from protective to pathogenic phenotypes. Beyond Th1/Th2 imbalance, Tregs and Th17 cells critically contribute to fibrosis. Emerging targeted strategies—including nanomaterials, natural compounds, and specific inhibitors—have shown promising preclinical results. Conclusion Understanding the spatiotemporally specific functions of immune cells is crucial for developing precision immunotherapies. Future research should focus on biomarker-guided combination strategies to transform RIPF into a preventable and manageable condition.
- 2 April 2026
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1) , 86
Multifaceted regulation of immune cells in radiation-induced pulmonary fibrosis: from mechanistic insights to targeted therapies
Background Radiation induced pulmonary fibrosis (RIPF) is a life threatening and frequent complication that can occur after radiotherapy to thoracic cancers, and has a complicated pathogenesis and few treatment options. Recent data suggest that immune cells are the centerpiece of this mechanism, and constitute a complex system of regulation. Objective This review systematically summarizes the dynamic roles and molecular mechanisms of key immune cells in RIPF initiation and progression, and reviews current advances in targeted immunotherapies. Methods A comprehensive literature search was conducted in PubMed and Web of Science for studies on immune regulation and therapeutic strategies in RIPF. Results RIPF exhibits profound spatiotemporal heterogeneity, with immune cell subsets evolving dynamically from inflammation to fibrosis. Macrophages transcend the M1/M2 dichotomy, encompassing specialized subsets. Neutrophils promote fibrosis via NETosis and STAT3/NLRP3 pathways, while eosinophils switch from protective to pathogenic phenotypes. Beyond Th1/Th2 imbalance, Tregs and Th17 cells critically contribute to fibrosis. Emerging targeted strategies—including nanomaterials, natural compounds, and specific inhibitors—have shown promising preclinical results. Conclusion Understanding the spatiotemporally specific functions of immune cells is crucial for developing precision immunotherapies. Future research should focus on biomarker-guided combination strategies to transform RIPF into a preventable and manageable condition.
- Open Access
- 29 May 2025
- Published by Springer Nature in Archives of Toxicology
- Vol. 99 (7) , 3055-3056
Correction: Mitigation of depleted uranium-induced mitochondrial damage by ethylmalonic encephalopathy 1 protein via modulation of hydrogen sulfide and glutathione pathways
- 29 May 2025
- Published by Springer Nature in Archives of Toxicology
- Vol. 99 (7) , 3055-3056
Open AccessCorrection: Mitigation of depleted uranium-induced mitochondrial damage by ethylmalonic encephalopathy 1 protein via modulation of hydrogen sulfide and glutathione pathways
- 27 December 2024
- Published by Springer Nature in Archives of Toxicology
- Vol. 99 (3) , 1133-1141
Mitigation of depleted uranium-induced mitochondrial damage by ethylmalonic encephalopathy 1 protein via modulation of hydrogen sulfide and glutathione pathways
Depleted uranium (DU) is a byproduct of uranium enrichment, which can cause heavy-metal toxicity and radiation toxicity as well as serious damage to the kidneys. However, the mechanism of renal injury induced by DU is still unclear. This study aimed to explore the role of ethylmalonic encephalopathy 1 (ETHE1) in DU-induced mitochondrial dysfunction and elucidate the underlying mechanisms. Using ETHE1 gene knockout C57BL/6 mice (10 mg/kg DU) and renal cell models (500 µM DU) exposed to DU, we observed significantly reduced levels of hydrogen sulfide (H2S) and glutathione (GSH), alongside decreased adenosine triphosphate (ATP) content and increased oxidative stress. Our results demonstrated that knocking out or silencing ETHE1 led to a significant reduction in H2S and GSH levels, whereas the opposite occurred when was ETHE1 overexpressed. When the H2S donor sodium hydrosulfide and GSH precursor N-acetylcysteine were used to treat animals or cells, cellular ATP levels were increased, oxidative stress markers were reduced, and kidney damage was mitigated. In addition, H2S and GSH interacted with each other after DU poisoning. These findings suggest that the ETHE1/H2S/GSH pathway plays a critical role in mediating DU-induced mitochondrial dysfunction in renal cells, highlighting potential therapeutic targets for mitigating the harmful effects of DU. Thus, this study expands our understanding of DU-induced renal damage pathways, providing avenues for further research and intervention strategies.
- 27 December 2024
- Published by Springer Nature in Archives of Toxicology
- Vol. 99 (3) , 1133-1141
Mitigation of depleted uranium-induced mitochondrial damage by ethylmalonic encephalopathy 1 protein via modulation of hydrogen sulfide and glutathione pathways
Depleted uranium (DU) is a byproduct of uranium enrichment, which can cause heavy-metal toxicity and radiation toxicity as well as serious damage to the kidneys. However, the mechanism of renal injury induced by DU is still unclear. This study aimed to explore the role of ethylmalonic encephalopathy 1 (ETHE1) in DU-induced mitochondrial dysfunction and elucidate the underlying mechanisms. Using ETHE1 gene knockout C57BL/6 mice (10 mg/kg DU) and renal cell models (500 µM DU) exposed to DU, we observed significantly reduced levels of hydrogen sulfide (H2S) and glutathione (GSH), alongside decreased adenosine triphosphate (ATP) content and increased oxidative stress. Our results demonstrated that knocking out or silencing ETHE1 led to a significant reduction in H2S and GSH levels, whereas the opposite occurred when was ETHE1 overexpressed. When the H2S donor sodium hydrosulfide and GSH precursor N-acetylcysteine were used to treat animals or cells, cellular ATP levels were increased, oxidative stress markers were reduced, and kidney damage was mitigated. In addition, H2S and GSH interacted with each other after DU poisoning. These findings suggest that the ETHE1/H2S/GSH pathway plays a critical role in mediating DU-induced mitochondrial dysfunction in renal cells, highlighting potential therapeutic targets for mitigating the harmful effects of DU. Thus, this study expands our understanding of DU-induced renal damage pathways, providing avenues for further research and intervention strategies.
- 19 January 2023
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 372, 110356
Depleted uranium causes renal mitochondrial dysfunction through the ETHE1/Nrf2 pathway
- 19 January 2023
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 372, 110356
Depleted uranium causes renal mitochondrial dysfunction through the ETHE1/Nrf2 pathway